Staff

	Amy Efantis President & CEO
Global Initiatives
John Delacourt Chief Legal Officer and Vice President, Global Initiatives	Larisa Cervenakova Medical Director	George Schreiber Director Epidemiology
Brenna Raines Assistant Director Global Health Policy	Abigail Glaser Administrative Assistant
Source & International Affairs
Joshua Penrod Senior Vice President Source & International Affairs	Sonia Balboni Director Source & Standards	Alexa Wetzel Director Source Europe
Julia Fabens Assistant Director International Affairs	Brenda Norman Senior Manager Data	Diana Krueger Manager IQPP Audits
	Bobbi Stackman Coordinator Source & International Affairs
Regulatory & Quality Policy
Mary Gustafson Vice President Global Regulatory Policy	Dominika Misztela Senior Director Regulatory Policy Europe	Bill Speir Senior Director Advocacy and Regulatory Policy
Michelle Fransen Project Manager Health Initiatives	Michelle Mason Coordinator Global Regulatory Policy/ QSEAL Administrator
Public Affairs, Europe
Maarten Van Baelen Executive Director Europe	Karl Petrovsky Director Health Policy	Sándor Tóth Senior Manager Government Affairs and Health Policy
Athina Giannoutsou Manager Public Affairs	Melanie Conrads Office Manager
Public Affairs, North America
Julie Birkofer Senior Vice President Public Affairs	Tom Lilburn Senior Director Government Relations	Mat Gulick Director Global Communications
Rachel Liebe Manager Global Communications	Tim Swope Manager Government Relations	Manisha Vasudeva Communications Specialist Global Communications
	April O'Neal Executive Assistant
Finance & Operations
Gene Stroshane Senior Director Finances & Operations	Cathy Izzi Senior Director Human Resources & Administrative Services	Mike McCormick Director IT & Facilities
	Charon Smith Senior Manager Accounts Receivables/Payables

PPTA News

Plasma Donors Should be Celebrated, not Denigrated +

The Guardian published an editorial on October 21 by Arwa Mahdawi that relies heavily on a 2015 article that intentionally sought to perpetuate a divisive representation of plasma donors’ commitments and motivations – Ms. Mahdawi used those negative insinuations in a broader attempt to castigate the U.S. and its public support programs. The Plasma Protein Therapeutics Association (PPTA) and its member companies are grateful for every plasma donor, each of whom directly contributes to saving and improving the lives of people facing serious, inherited, and life-threatening diseases.

Today, when faced with a significant decline in plasma donations due to the ongoing COVID-19 pandemic, every plasma donor deserves our deepest respect, gratitude, and appreciation, not negative characterizations and stereotypes. Even Ms. Mahdawi understands how essential plasma donation is by noting “it is something we should all do if we can: plasma is desperately needed for life-saving therapies.”

Patients around the world who rely on plasma-derived therapies could not agree more. In fact, because of the sharp decline in plasma donation wrought by the current pandemic, we can reasonably expect that the reduction in plasma collections currently being experienced could cause challenges to patient access in the months to come.

Ms. Mahdawi clearly does not object to compensating plasma donors, “as long it is strictly regulated, the number of donations safely capped, and the pay fair.” This industry is committed to the health and safety of every person who donates plasma at approximately 1,000 plasma donation centers in the United States and in Europe, and it adheres to stringent regulations, both in the U.S. and internationally, so that only those who are healthy enough to donate plasma can do so. Additionally, PPTA member companies’ plasma collection centers are certified by the International Quality Plasma Program, a rigorous, voluntary program that goes beyond regulatory requirements to help ensure donor safety. Although different countries have varying regulations regarding plasma collection, no single regulatory scheme is better than another; all regulations are in place to ensure donor safety and the safety and efficacy of the finished therapies.

While people’s reasons for donating their plasma are as varied as the diseases treated by access to plasma protein therapies, it is true that some people do so to lessen financial stress or to earn some extra income to help friends or loved ones. A letter published in 2018 by more than two dozen ethicists and economists explains that compensating donors is ethical and is intended to recognize their commitment and inconvenience.

Quite simply, plasma donors save lives, and PPTA, its member companies, and patient stakeholder groups worldwide continue to advocate with local, regional, national, and international authorities to address donation shortfalls seen because of the pandemic. Further, we are using our collective voices to raise awareness of the urgent need for plasma donation. While we are glad that Ms. Mahdawi recognizes how essential plasma donation is for countless individuals, perhaps she would consider using her editorial space to urge her readers to donate by helping them understand how essential they are and how urgent the need is, rather than insulting and victimizing plasma donors and the patients who rely on plasma-derived therapies as part of an attempt to critique public support programs.
Read More
International Plasma Awareness Week 2020: Be a Hero, Donate Plasma Today +

ANNAPOLIS, MD (October 5, 2020) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the eighth annual International Plasma Awareness Week (IPAW), which will run until October 9.
Read More
New York and California recognize the importance of plasma donation +

The Plasma Protein Therapeutics Association (PPTA) is pleased by recent actions taken in California and New York, two of the most populous states in the country, that show the growing recognition of the importance of plasma donation. In New York, the Department of Health released emergency regulations that revise requirements for the Collection of Blood Components. These revisions simplify the regulatory landscape for source plasma¹ donation in New York by harmonizing New York State requirements with national standards. The changes should enhance plasma availability, while maintaining high blood safety standards.
Read More
PPTA Testifies at USITC COVID-19 Related Goods Hearing +

On Wednesday, September 23, at the invitation of the U.S. International Trade Commission (USITC), PPTA President & CEO, Amy Efantis testified before the USITC at a virtual hearing on COVID-19 Related Goods: The U.S. Industry, Market, Trade, and Supply Chain Challenges. The main messages that PPTA conveyed were that the plasma protein therapeutics industry is built on a complex, global supply chain that must be preserved to ensure access for the patients that depend on it. Additionally, it is of vital importance that the Administration continue to support policies that encourage plasma donation.
Read More

1
2
3

› ‹

Mission Video

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap